Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYi YuWCWeihao ChenJSJimin Shi

Discussion

Loading...

Member takes

Overview

Phase II trial shows 85.8% relapse-free survival in T-cell lymphoma patients post-allogeneic stem cell transplant, indicating promise for chidamide maintenance therapy.

Key Points

  • Overall survival rate reached 89.4% at two years post-transplant for patients receiving chidamide.
  • With acute graft-versus-host disease incidence at 38.5%, maintenance therapy proves manageable after allo-HSCT.
  • The treatment saw low rates of hematological toxicities like neutropenia and thrombocytopenia during the trial.
  • Relapse-free survival exceeded 85%, suggesting chidamide may sustain remission long-term in aggressive lymphomas.

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfb5https://doi.org/10.1182/blood-2025-169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness and safety profile of chidamide as maintenance therapy for peripheral T-cell lymphoma: a multicenter real-world study2025
  2. 2A prospecitive, multicenter study of chidamide in adult patients with refractory primary immune thrombocytopenia2025
  3. 3Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma2025
  4. 4Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity2025
  5. 5Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia2025